Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (432)	6/15/1999 12:10:00 PM
From: scaram(o)uche	Respond to of 3158

Not sexy enough, and a bad fit. That was the opinion of my contact at the underwriter, not mine. I honestly feel that the Adcon business could be retained as a separate unit, a very profitable and tidy one. Given the focus on obesity, seems like "brain inflammation" would be a great fit...... not to mention the properdin MAb. I forget the three companies that I had mentioned as a melded "Millennium, Neurobiology"...... SIBI, GLIA and NRGN?? I had first mentioned GLFD, but remember having later dropped it. Maybe I had just left it at SIBI and NRGN. Now, I'd say SIBI, GLIA, and NBIX. Not complex at all. :-) I do not understand the nature of GLIA trading..... it's had me muddled for ages. I can't understand why it's not a $60 stock. Cheers! Rick

To: RCMac who wrote (432)	6/15/1999 12:14:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 3158

Well we have a kind-of horizontal merger between two of the better UK 2nd/3rd tier biotechs - Celltech and Chiroscience. Although the two companies are about the same size, Celltech CEO ends up in control and it was at a premium to CRO's price, so really this was Celltech gobbling CRO. Message 10123361 Further details at: celltech.co.uk Combined companies will have a market cap comfortably over $1 billion. Chiroscience closed up about 9% in London on the news, with Celltech off about 2%. Peter